Showing results (41-50 of 52) with videos related to
Sort By:
Pageof 6
The New England Journal of Medicine|August 9, 2013
Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndromeAmi S Bhatt, Samuel S Freeman, Alex F Herrera, et al.Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRuben Mesa, Catriona Jamieson, Ravi Bhatia, et al.Haematologica|December 31, 2016
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemiaAmir T Fathi, Seth A Wander, Traci M Blonquist, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 6, 2020
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMichael W Deininger, Neil P Shah, Jessica K Altman, et al.Cancer|September 30, 2017
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutationAmir T Fathi, Traci M Blonquist, Daniela Hernandez, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2018
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJerald P Radich, Michael Deininger, Camille N Abboud, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2017
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018Ruben A Mesa, Catriona Jamieson, Ravi Bhatia, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 4, 2020
Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in OncologyAaron T Gerds, Jason Gotlib, Prithviraj Bose, et al.Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017Arnel Pallera, Jessica K Altman, Ellin Berman, et al.Cancer|December 21, 2019
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemiaRupa Narayan, Traci M Blonquist, Ashkan Emadi, et al.Pageof 6